|
 |
European Pharmaceutical Contractor
|
Clinical development accounts for 60 to 70 per cent of the time needed to get a new chemical entity (NCE) to market and over the years, conscientious clinical teams have done all they can to reduce the risk of study delays and to minimise the impact of any setbacks. And indeed there have been considerable successes along the way. Since the 1980s, pharma companies have been able to complement their own resources by calling upon contract research organisations (CROs) to avoid delays caused by lack of resources or inexperience in a particular therapeutic area. More recently, technology and centralised dispatch systems have been used to ensure the timely, reliable distribution of clinical trial supplies to sites actively recruiting patients, while electronic data capture offers the potential to speed up data management and create a real-time study database.
Delay, What Delay?
As each source of delay is identified and overcome, it is hard to ignore the fact that many studies in Western Europe are delayed by poor patient recruitment. Most professionals involved in clinical trials will have experienced this problem first-hand and the published evidence for it is growing. Last year, the British Medical Journal reported that Britain has a poor patient recruitment record, achieving less than 80 per cent of the patients promised (1).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
